Anales de la RANM

151 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 PEQUEÑAS MOLÉCULAS EN EL TRATAMIENTO DE LA PSORIASIS Martos-Cabrera L, et al. An RANM. 2023;140(02):142 - 152 • Esteban Daudén realiza o ha realizado las siguientes actividades: miembro de Advisory Board, consultor, recepción de becas, apoyo a la investigación, participación en ensayos clínicos, honorarios por impartir ponencias, con las siguientes compañías farmacéuticas: Abbott/Abbvie, Almirall, Amgen, Biogen, Celgene, Janssen-Cilag, Leo Pharma, Lilly, MSD, Novartis, Pfizer, UCB, Brystol-Myers y Boehringer-Ingelheim. FINANCIACIÓN No. BIBLIOGRAFÍA 1. Boehncke WH, Schön MP. Psoriasis. Lancet. 2015; 386(97): 983-994. 2. Parisi R, Symmons DPM, Griffiths CEM, Ash- croft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013; 133(2): 377-385. 3. Llamas-Velasco M, de la Cueva P, Notario J, Martínez-Pilar L, Martorell A, Moreno-Ramírez D. Psoriasis moderada: Propuesta de definición. Actas Dermosifiliogr. 2017; 108(10): 911-917. 4. Takeshita J, Grewal S, Langan SM et al. Psoriasis and comorbid diseases. J Am Acad Dermatol. 2017; 76(3): 377-390. 5. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JN. Psoriasis Lancet. 2021; 397(10281): 1301-1315. 6. Dand N, Mahil S, Capon F, Smith C, Simpson M, Barker J. Psoriasis and genetics. Acta Derm Venerol. 2020; 100(3): 55-65. 7. Shobeiri SS, Khorrami M, Sankian M. Plaque- type psoriasis inhibitors. Int Immunopharma- col. 2021; 101(1): 108326. 8. Talamonti M, D’Adamio S, Bianchi L, Galluz- zo M. The role of pharmacogenetics in chronic plaque psoriasis: Update of the literature. Mol Diagn Ther. 2017; 21(5): 467-480. 9. van Vugt LJ, van den Reek JMPA, Coenen MJH, de Jong EMGJ. A systematic review of pharma- cogenetic studies on the response to biologics in patients with psoriasis. Br J Dermatol. 2018; 178(1): 86-94. 10. Linares-Pineda TM, Cañadas-Garre M, Sán- chez-Pozo A, Calleja-Hernández MÁ. Gene po- lymorphisms as predictors of response to biolo- gical therapies in psoriasis patients. Pharmacol Res. 2016; 113(1): 71-80. 11. Ovejero-Benito MC, Prieto-Pérez R, Llamas- Velasco M et al. Polymorphisms associated with etanercept response in moderate-to-severe pla- que psoriasis. Pharmacogenomics. 2017; 18(7): 631-638. 12. Reid C, Griffiths C. Psoriasis and treatment: past, present and future aspects. Acta Derm Ve- nerol. 2020;100(3):70-80. 13. Tang H, Jin X, Li Y et al. A large-scale screen for coding variants predisposing to psoriasis. Nat Genet. 2014; 46(1): 45-50. 14. Gómez-García F, Gómez-Arias PJ, Montilla- López A et al. A scoping review on use of drugs targeting the JAK/STAT pathway in psoriasis. Front Med. 2022;(1)754116. 15. Gooderham M. Small molecules: an overview of emerging therapeutic options in the treatment of psoriasis. Skin Therapy Lett. 2013; 18(7): 1-4. 16. Thakur V, Mahajan R. Novel therapeutic target(s) for psoriatic disease. Front Med. 2022;9(1):712313. 17. Honma M, Hayashi K. Psoriasis: Recent pro- gress in molecular‐targeted therapies. J Derma- tol. 2021; 48(6): 761-777. 18. Balogh EA, Bashyam AM, Ghamrawi RI, Feldman SR. Emerging systemic drugs in the treatment of plaque psoriasis. Expert Opin Emerg Drugs. 2020; 25(2): 89-100. 19. Cervantes-Durán C, Velázquez-Hernández ME, Valentín-Escalera J, Bartolomé-Camacho MC, Rodríguez-Orozco AR, García-Pérez ME. Small molecules under development for psoriasis: on the road to the individualized therapies. Arch Dermatol Res. 2020; 312(9): 611-627. 20. Hansen RB, Kavanaugh A. Novel treatments with small molecules in psoriatic arthritis. Curr Rheumatol Rep. 2014; 16(9):443. 21. Milakovic M, Gooderham MJ. Phosphodieste- rase-4 inhibition in psoriasis. Psoriasis. 2021; 11(1): 21-29. 22. Garcet S, Nograles K, Correa da Rosa J, Schafer PH, Krueger JG. Synergistic cytokine effects as apremilast response predictors in patients with psoriasis. J Allergy Clin Immunol. 2018; 142(3): 1010-1013. 23. Strober B, Alikhan A, Lockshin B, Shi R, Cirulli J, Schafer P. Apremilast mechanism of efficacy in systemic-naive patients with moderate pla- que psoriasis: Pharmacodynamic results from the UNVEIL study. J Dermatol Sci. 2019; 96(3): 126-133. 24. Papp K, Reich K, Leonardi CL et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibi- tor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Eva- luating the Effects of Apremilast in Psoria- sis [ESTEEM 1]). J Am Acad Dermatol. 2015; 73(1): 37-49. 25. Paul C, Cather J, Gooderham M et al. Efficacy and safety of apremilast, an oral phosphodies- terase 4 inhibitor, in patients with moderate‐to‐ severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015; 173(6): 1387-1399. 26. Aljefri YE, Ghaddaf AA, Alkhunani TA et al. Efficacy and safety of apremilast monotherapy in moderate-to-severe plaque psoriasis: a sys- tematic review and meta-analysis. Dermatol Ther. 2022; 35(7): e15544. 27. Herranz P, Trasobares L, Mateu A et al. Caracte- rización y resultados de pacientes tratados con apremilast en la práctica clínica habitual espa- ñola: Resultados del estudio APPRECIATE. Ac- tas Dermosifiliogr. 2021; 112(9): 817-827.